Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
FMR LLC and Abigail P. Johnson report updated ownership in Insulet Corp common stock on a Schedule 13G/A. FMR LLC is shown as beneficially owning 964,296.97 shares, representing 1.4% of the class. FMR LLC has sole voting power over 692,986.46 shares and sole dispositive power over 964,296.97 shares, with no shared voting or dispositive power. The filing notes that one or more other persons have rights to dividends or sale proceeds in these shares, but no single such person holds more than five percent of Insulet’s outstanding common stock.
Insulet Corporation reported strong results for the three months ended June 30, 2026. Revenue reached $801.7 million, up 23.5% (22.7% in constant currency), led by Omnipod revenue of $795.9 million. U.S. Omnipod grew 20.1% to $544.1 million, while International Omnipod rose 35.5% to $251.8 million. Operating income was $129.7 million, or 16.2% of revenue, and adjusted operating income was $154.5 million, or 19.3% of revenue. Net income increased to $95.0 million, or $1.37 per diluted share, and adjusted diluted EPS was $1.66.
For the six months ended June 30, 2026, revenue was $1,563.4 million and free cash flow was $145.4 million. For full‑year 2026, Insulet now expects constant‑currency revenue growth of 20%–22%, compared with prior guidance of 21%–23%, and continues to target about 100 basis points of adjusted operating margin expansion. The outlook for adjusted EPS growth is now >30%, compared with >25% in prior guidance. Third‑quarter 2026 constant‑currency revenue growth is projected at 18%–20% for Total Omnipod and 17.5%–19.5% for the Company overall.
Strategically, Insulet expanded Omnipod 5 and Omnipod into Spain, enhanced the Omnipod 5 algorithm and sensor compatibility, presented new clinical data on Omnipod 6 and a fully closed‑loop technology for people with type 2 diabetes, and partnered with Calm to provide mindfulness, sleep and stress‑management tools for the diabetes community.
Insulet Corp executive Lisa Blair Davis, SVP and Chief HR Officer, reported a tax-withholding disposition of 244 shares of common stock on 2026-08-01 at $165.35 per share to cover RSU-related tax obligations. After this withholding, she directly holds 4,453 shares, including 80 shares acquired through the Employee Stock Purchase Plan.
Insulet Corp director Robert Luther Huffines reported an amended grant of 151 deferred common stock units received in lieu of cash fees under the company’s Deferred Compensation Plan for Non-Employee Directors. These Deferred Units convert into common stock on a one-for-one basis upon distribution.
The amendment corrects an administrative error in the original Form 4, revising the award to 151 units at a price of $152.25 per unit, instead of 144 units at $159.79. Following this adjustment, Huffines holds 2,449 shares directly.
INSULET CORP director Jonathan Jay Mazelsky received an initial equity award in the form of restricted stock units, which convert into common shares on a one-for-one basis. The award covers 1,355 shares of common stock at a stated price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase.
After this grant, Mazelsky directly holds 1,355 shares of Insulet common stock according to the filing. The transaction is categorized as a grant, award, or other acquisition of non-derivative common stock, tied to his role on the company’s board.
INSULET CORP director Jonathan Jay Mazelsky has filed an initial Form 3 showing no current ownership of the company’s Common Stock. The filing lists him as a director and reports total Common Stock holdings of 0 shares following the reported position. This is an administrative disclosure of his starting ownership status as an insider, and it does not reflect any recent buy or sell transaction in the stock.
INSULET CORP director Robert Luther Huffines received a grant of 144 deferred common stock units, valued at $159.79 per unit. These units were awarded as non-cash compensation under the Company’s Deferred Compensation Plan for Non-Employee Directors and will convert into common shares on a one-for-one basis upon distribution.
After this grant, Huffines is reported as directly holding 2,442 shares of common stock. Distribution of the underlying shares will occur in either a lump sum or substantially equal annual installments, at the director’s election under the plan.
Insulet Corporation appointed Jonathan J. (Jay) Mazelsky as a Class II member of its Board of Directors, effective July 1, 2026. He will stand for election at the Company’s 2027 annual stockholder meeting and will serve as an independent director.
Mazelsky is Executive Chair of IDEXX Laboratories’ board and previously served there as President and CEO, with prior leadership roles at Philips Healthcare, Agilent Technologies, and Hewlett Packard. As a non-employee director, he will receive an initial grant of restricted stock units with a grant date fair value of $216,548, representing a pro-rated $260,000 annual equity award, plus cash compensation under Insulet’s non-employee director compensation program. The Company states there are no related-party arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.
INSULET CORP director Timothy C. Stonesifer bought shares of the company in the open market. On June 3, he purchased 2,790 shares of Insulet common stock at $143.51 per share. After this transaction, his direct holdings increased to 9,041 common shares.